CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
research
Clinical trial of FK 506 immunosuppression in adult cardiac transplantation
Authors
Armitage
Bartley P. Griffith
+16 more
Billingham
Dew
Fung
Gary C. Marrone
John Fung
John M. Armitage
Kormos
Kusne
Robert L. Hardesty
Robert L. Kormos
Shigeki Morita
Starzl
Starzl
Tamura
Thomas E. Starzl
Todo
Publication date
1 January 1992
Publisher
'Elsevier BV'
Doi
Cite
View
on
PubMed
Abstract
The new immunosuppressive agent FK 506 was used as primary immunotherapy in conjunction with low-dose steroids and azathioprine in 72 patients subsequent to orthotopic cardiac transplantation. Overall patient survival at a mean follow-up of 360 days was 92%. The number of episodes of cardiac rejection (grade 3A or greater) within 90 days of transplantation was 0.95 per patient. The actuarial freedom from rejection at 90 days was 41%. Achievement of this level of immunosuppression is comparable with that of cyclosporine-based triple-drug therapy with OKT3 immunoprophylaxis. Thirty percent of patients were tapered off all steroids, and the average steroid dose in the group who received steroids was 8.6 mg of prednisone per day. The incidence of infection reflected the diminished necessity for steroids: seven major infections (10%) and 11 minor infections (16%). Renal dysfunction occurred during the perioperative period in most patients in this trial. However, the incidence of hypertension was 54% compared with 70% during the cyclosporine era. Ten adults underwent successful rescue therapy with FK 506 after cardiac rejection refractory to conventional immunotherapy. Side effects of FK 506 were notably few, and the results of the trial are encouraging for the future of the cardiac transplant recipient. © 1992
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
D-Scholarship@Pitt
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:d-scholarship.pitt.edu:478...
Last time updated on 19/07/2013
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
info:doi/10.1016%2F0003-4975%2...
Last time updated on 05/06/2019